Influenza A virus-IN-18 

Influenza A virus-IN-18 (Compound C2e) is an orally active inhibitor of Influenza A virus (IC₅₀: 2.5 μM against PR8/H1N1; 6.42 μM against H3N2). Influenza A virus-IN-18 binds directly to the H1N1/PR8 HA protein with high affinity, with a K_D of 0.25 μM. Influenza A virus-IN-18 is applicable to research related to Influenza A virus infection^[1].

Influenza A virus-IN-18 (1.25-20 μM) binds directly to H1N1/PR8 HA protein with high affinity, exhibiting a K_D of 0.25 μM^[1].
Influenza A virus-IN-18 (48 h) potently inhibits H1N1 virus replication in MDCK cells with an IC₅₀ of 2.5 μM and exhibits no cytotoxicity at concentrations up to 300 μM^[1].
Influenza A virus-IN-18 (48 h) inhibits H3N2 virus replication in MDCK cells with an IC₅₀ of 6.42 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Influenza A virus-IN-18 (C2e) (2.5-5 mg/kg/day; p.o.; once a day) achieves a survival rate over 50% in H1N1-infected BALB/c mice, with superior weight recovery compared to control treatments^[1].
Influenza A virus-IN-18 (1000 mg/kg; p.o.; single dose) is well tolerated in ICR mice, with no observed toxicity or organ pathology^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

628.71

C₃₅H₄₀N₄O₇

3085746-63-7

OC1=C(C=C(C(O)=C1CC2=C(NC3=CC(NC(CN4CCN(CC4)C)=O)=CC=C32)CC5=C(C(C)=CC(C(C)=O)=C5O)O)C(C)=O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gai W, et al. Pocket-Based Generative Diffusion Model Accelerates Potent Influenza A Hemagglutinin Inhibitor Discovery. J Med Chem. 2026;69(4):4969-4983.  [Content Brief]